82 related articles for article (PubMed ID: 7585575)
21. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
22. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
24. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
[TBL] [Abstract][Full Text] [Related]
25. 5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs.
Efferth T; Futscher BW; Osieka R
Blood Cells Mol Dis; 2001; 27(3):637-48. PubMed ID: 11482878
[TBL] [Abstract][Full Text] [Related]
26. Effects of RIalpha overexpression on cisplatin sensitivity in human ovarian carcinoma cells.
Cvijic ME; Chin KV
Biochem Biophys Res Commun; 1998 Aug; 249(3):723-7. PubMed ID: 9731205
[TBL] [Abstract][Full Text] [Related]
27. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
28. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells.
Hirama M; Isonishi S; Yasuda M; Ishikawa H
Oncol Rep; 2006 Nov; 16(5):997-1002. PubMed ID: 17016583
[TBL] [Abstract][Full Text] [Related]
29. Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16.
Mirakhur B; Parekh HK; Simpkins H
Cancer Res; 1996 May; 56(10):2256-62. PubMed ID: 8625294
[TBL] [Abstract][Full Text] [Related]
30. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin.
Solár P; Horváth V; Kleban J; Koval' J; Solárová Z; Kozubík A; Fedorocko P
Neoplasma; 2007; 54(2):127-30. PubMed ID: 17319785
[TBL] [Abstract][Full Text] [Related]
31. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
32. [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
Jin Z; Guan T; Li S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun; 19(3):218-20. PubMed ID: 12048682
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Basu A; Weixel K; Saijo N
Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of intracellular nm23-H1 prevents cisplatin-induced DNA damage in oesophageal cancer cells: possible association with Na(+), K(+)-ATPase.
lizuka N; Miyamoto K; Tangoku A; Hayashi H; Hazama S; Yoshino S; Yoshimura K; Hirose K; Yoshida H; Oka M
Br J Cancer; 2000 Nov; 83(9):1209-15. PubMed ID: 11027435
[TBL] [Abstract][Full Text] [Related]
36. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
37. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.
Lenzi R; Frost P; Abbruzzese JL
Anticancer Res; 1994; 14(1A):247-51. PubMed ID: 7513143
[TBL] [Abstract][Full Text] [Related]
38. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
39. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
Chen G; Zeller WJ; Todorov DK
Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
[TBL] [Abstract][Full Text] [Related]
40. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]